{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:45:01Z","timestamp":1761518701696},"reference-count":17,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2002,1,5]],"date-time":"2002-01-05T00:00:00Z","timestamp":1010188800000},"content-version":"vor","delay-in-days":1192,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Internal Medicine"],"published-print":{"date-parts":[[1998,10]]},"abstract":"<jats:sec><jats:label \/><jats:p>Chowdhury TA, Dyer PH (Birmingham Heartlands Hospital, Birmingham, UK). Clinical, biochemical and immunological characteristics of relapsers and non\u2010relapsers of thyrotoxicosis treated with anti\u2010thyroid drugs. <jats:italic>J Intern Med<\/jats:italic> 1998; <jats:bold>244<\/jats:bold>: 293\u2013297.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study aims to correlate clinical, biochemical and immunological factors seen at diagnosis of thyrotoxicosis with subsequent relapse within 5 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Retrospective review of case notes, and biochemical assessment at least 5 years after cessation of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>A large general hospital endocrine clinic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Subjects<\/jats:title><jats:p>Patients presenting with a first episode of thyrotoxicosis between 1988 and 1991 who were treated with antithyroid drugs for at least 18 months.<\/jats:p><jats:p>Main outcome measures. Relapse was determined by examination of hospital records, general practice records, patient questionnaire and thyroid function tests.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 216 subjects presented for the first time with thyrotoxicosis, of whom 89 (41.2%) suffered a relapse of the disease. On univariate analysis, clinical factors associated with increased relapse include younger age at diagnosis, goitre, marked tachycardia, requirement for higher maintenance dose of carbimazole, higher FT<jats:sub>4<\/jats:sub> levels at diagnosis and smoking. Factors not predictive of relapse include presence of thyroid eye signs, positive family history, atrial fibrillation or congestive cardiac failure, acropachy or pretibial myxoedema, and presence or absence of thyroid autoantibodies. Logistic regression analysis showed relapse was predominantly determined by an FT<jats:sub>4<\/jats:sub> &gt; 56.2 nmol L<jats:sup>\u22121<\/jats:sup>, pulse rate &gt; 110, presence of goitre and a positive smoking history (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>= 0.36, <jats:italic>P<\/jats:italic> &lt; 0.001). Presence of these four factors predicted relapse in 76 (85.4%) of the 89 patients who relapsed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Increased \u2018toxicity\u2019 of thyrotoxicosis, goitre and smoking are associated with relapse of thyrotoxicosis, and this may be helpful in determining which patients may be better managed with early ablative therapy.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2796.1998.00320.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T06:07:40Z","timestamp":1047449260000},"page":"293-297","source":"Crossref","is-referenced-by-count":11,"title":["Clinical, biochemical and immunological characteristics of relapsers and non\u2010relapsers of thyrotoxicosis treated with anti\u2010thyroid drugs"],"prefix":"10.1111","volume":"244","author":[{"given":"T. A.","family":"Chowdhury","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. H.","family":"Dyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,5]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1977.tb01340.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104043241403"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-70-3-675"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198411223112106"},{"key":"e_1_2_5_6_2","first-page":"1","article-title":"The management of hyperthyroidism due to Graves disease in Europe in 1986. Results of an international survey.","volume":"115","author":"Clinder D","year":"1987","journal-title":"Acta Endocrinol (Copenh)"},{"key":"e_1_2_5_7_2","first-page":"325","article-title":"Five year follow up of thyrotoxicosis treated with anti\u2010thyroid drugs.","volume":"63","author":"Thalassinos NC","year":"1974","journal-title":"Endokrinologie"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601253340403"},{"key":"e_1_2_5_9_2","first-page":"622","article-title":"Factors influencing the outcome of thyrostatic drug therapy in Graves' disease.","volume":"122","author":"Winsa B","year":"1990","journal-title":"Act Endocinol (Copenh)"},{"key":"e_1_2_5_10_2","first-page":"409","article-title":"Prediction of outcome in Graves' disease after carbimazole treatment.","volume":"59","author":"Weetman AP","year":"1986","journal-title":"QJ Med"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-62-5-980"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91315-2"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-51-4-863"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)91551-2"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-68-6-1097"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.78.1.98"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03347788"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6856.727"}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2796.1998.00320.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2796.1998.00320.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T07:24:42Z","timestamp":1698477882000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2796.1998.00320.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,10]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1998,10]]}},"alternative-id":["10.1046\/j.1365-2796.1998.00320.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2796.1998.00320.x","archive":["Portico"],"relation":{},"ISSN":["0954-6820","1365-2796"],"issn-type":[{"value":"0954-6820","type":"print"},{"value":"1365-2796","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,10]]}}}